mailed to the PTO on May 15, 2000 and as mailed to the PTO a second time on January 4, 2002;

(2) Supplemental Information Disclosure Statement, Form PTO-1449 in duplicate and copies of two listed references;

(2) New substitute paper copy of the Sequence Listing;

(3) New substitute CRF of the Sequence Listing (the requisite statement regarding the paper and CRF copies of the Sequence Listing is set forth below in the Remarks section);

(4) Copy of the Notice to Comply with the Sequence Listing Requirements;

(5) Formal drawings; and

(6) Marked-up version of the amendment to the specification.

IN THE CLAIMS:

Please cancel claims 44 - 51 without prejudice to applicants' prosecuting claims of identical or similar scope in one or more divisional or continuation applications.

Please add the following new claims 52 - 61:

---

52. (new) A method of extending the serum half-life of an antibody having a first IgG region capable of binding to FcRb receptor, the method comprising:

D1

linking to said antibody at least a second IgG region capable of binding to FcRb receptor in a pH-dependent manner,

wherein said antibody binds FcRb receptor with greater avidity at pH 6.0 after said linking.

53. (new) The method of claim 52, wherein any one of said first or at least second IgG regions comprises an IgG Fc region.

54. (new) The method of claim 52, wherein any one of said first or at least second IgG regions comprises an IgG hinge-CH2-CH3 region.

55. (new) The method of claim 54, wherein said hinge is a mutated hinge comprising one less cysteine residue than the corresponding wild type hinge.

D1

56. (new) The method of claim 52, wherein any one of said first or at least second IgG regions comprises an IgG CH2-CH3 region.

57. (new) An antibody with extended serum half-life, produced by the method of any one of claims 52 - 56.

58. (new) An antibody with an extended serum half-life, said antibody comprising:

a first IgG region capable of binding FcRb receptor; and

at least a second IgG region capable of binding FcRb receptor,

wherein said at least second IgG region confers upon said antibody avidity of binding FcRb receptor at pH 6.0 greater than that of said antibody lacking said at least second IgG region,